2026 BSSC Keynote Speakers

---

Founder at Stillwave

Topic: TBD

Chito Hernandez is the founder of Stillwave, an executive coaching company that embodies the philosophy of finding stillness amidst chaos. Building on a successful career as a life science executive, and now as Professor of Practice at UC San Diego, Chito leverages his expertise to guide the next generation of leaders. He empowers them to pause, reflect, and navigate complexities with clarity and purpose. Through tailored coaching, Chito fosters resilience and adaptability, helping leaders align their actions with their core values.

Chito has led multiple organizations throughout his career. He most recently served as Group Vice President of Data Science at BioMarin, a world leading biotechnology company focused on rare diseases. In addition, Chito is the Founder of FocusQ, an executive consulting firm that he established in the San Francisco Bay Area. Chito held Vice President positions at Elan Pharmaceuticals and Janssen Alzheimer Immunotherapy R&D. He has also made noteworthy contributions to the development of several drugs, eight of which have received regulatory approvals, with seven of them being the first in their class.  Additionally, he serves on boards dedicated to help organizations scale and sustain their impact.

Executive Chairman and Co-Founder of Equillium, Inc.

Topic: TBD

Dan Bradbury is a Life Sciences Executive with over 40 years of experience creating and

implementing strategies that transform businesses, bring novel medicines to market, and

maximize shareholder value. He is the Managing Member of BioBrit, LLC, a Life Sciences

Consulting and Investment Firm based in La Jolla, CA.

Dan is the Executive Chairman and Co-Founder of Equillium, Inc. (NASDAQ: EQ), a publicly traded

biopharmaceutical company based in La Jolla, CA, focused on developing products to treatsevere

autoimmune and inflammatory disorders with high unmet medical need. He served as Chief

Executive Officer of Equillium until January 2020. He is the former President, Chief Executive

Officer, and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San

Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company

launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes,

and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March

2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Before joining Amylin,

Dan worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals.

Dan serves on the board of directors of Castle Biosciences, Inc. (NASDAQ: CSTL), Equillium, Inc.

(NASDAQ: EQ), Vivani Medical, Inc. (NASDAQ: VANI) and a number of private companies and

philanthropic organizations.

Dan received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management

Studies from the University of West London in the United Kingdom.

Chief Medical Officer, Precision for Medicine

Topic: TBD

Dr. Harpreet Singh serves as Chief Medical Officer of Precision for Medicine, a global leader in biomarker-driven clinical research and development.  Dr. Singh was previously an Oncology Division Director at the U.S. Food and Drug Administration (FDA) and is responsible for medical strategy and oversight at Precision.

She is an experienced leader with a demonstrated track record in building high performing cross functioning teams, developing and maintaining excellent working relationships with colleagues in academia, industry, and international regulatory bodies. Dr. Singh is scientifically driven, patient centered, with high academic integrity and a commitment to regulatory standards.

Motivated by a desire to accelerate breakthrough treatments in oncology and rare disease, Dr. Singh has a multi-dimensional understanding of drug development along with deep experience as a medical oncologist, having trained at the National Cancer Institute and the University of Southern California Keck School of Medicine. Dr. Singh maintains an active public presence as a thought leader for important issues facing the life sciences industry.